VECTORITE BIOMEDICAL INC. Vectorite Biomedical Inc. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was TWD 16 million compared to TWD 12.44 million a year ago. Net loss was TWD 16.02 million compared to net income of TWD 20.02 million a year ago.
Basic loss per share from continuing operations was TWD 0.3626 compared to basic earnings per share from continuing operations of TWD 0.478 a year ago. Diluted loss per share from continuing operations was TWD 0.3626 compared to diluted earnings per share from continuing operations of TWD 0.478 a year ago.
